Aktuelle Neurologie 2014; 41(03): 156-161
DOI: 10.1055/s-0034-1370995
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Aktuelle Therapie der Sepsis auf der neurologischen Intensivstation
Teil 1: generelle Aspekte der Sepsistherapie

Current Aspects of Sepsis Therapy on Neurointensive Care Units
Part 1: General Aspects of Sepsis Therapy
B. Rosengarten
1   Neurologie, Universitätsklinikum Giessen und Marburg GmbH, Campus Gießen
,
K. Mayer
2   Internal Medicine, University Clinics Giessen and Marburg GmbH Campus Gießen
,
C. Lichtenstern
3   Klinik für Anästhesiologie, Operative Intensivmedizin, Universitätsklinikum Gießen und Marburg
› Author Affiliations
Further Information

Publication History

Publication Date:
09 April 2014 (online)

Zusammenfassung

Die Sepsis ist eine wieder häufiger werdende Erkrankung. Das liegt am demografischen Wandel, an der Zahl immun-supprimierter Patienten und auch an der Multiresistenz der Erreger. Neurologische Aspekte der Sepsis sind wichtig, da das Gehirn schon sehr früh vom inflammatorischen Geschehen betroffen ist, und neuronale Schäden bei Überlebenden im Wesentlichen die Schwere der Invalidisierung bestimmen. Als Einstieg in das Erkrankungsbild der Sepsis werden in der folgenden Übersicht aktuelle Aspekte der allgemeinen Sepsisforschung dargestellt, bevor in einem 2. Teil spezielle neurologische Aspekte behandelt werden.

Abstract

Summary Sepsis is once again increasing in frequency. This is due to demographic changes, increasing number of immunosuppressed patients and also the increasing multiresistance of microorganisms. Neurological aspects in sepsis therapy are important, as the brain is affected early by inflammatory processes, and neuronal damage mainly determines the severity of invalidity in sepsis survivors. In the first part, an overview of the general aspects of current sepsis research will be given as an introduction to the clinical picture of sepsis, and in the second part, special neurological aspects will be addressed.

 
  • Literatur

  • 1 Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138-150
  • 2 Angus DC, Wax RS. Epidemiology of sepsis: an update. Crit Care Med 2001; 29: S109-S116
  • 3 Martin GS, Mannino DM, Eaton S et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-1554
  • 4 Brunkhorst FM, Engel C, Ragaller M et al. Practice and perception – a nationwide survey of therapy habits in sepsis. Critical care medicine 2008; 36: 2719-2725
  • 5 Engel C, Brunkhorst FM, Bone HG et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive care medicine 2007; 33: 606-618
  • 6 Naucler P, Darenberg J, Morfeldt E et al. Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia. Thorax 2013; 68: 571-579
  • 7 Klemets P, Lyytikainen O, Ruutu P et al. Invasive pneumococcal infections among persons with and without underlying medical conditions: implications for prevention strategies. BMC Infect Dis 2008; 8: 96
  • 8 Nguyen HB, Corbett SW, Steele R et al. Implementation of a bundle of quality indicators for the early management of severe sepsis and septic shock is associated with decreased mortality. Crit Care Med 2007; 35: 1105-1112
  • 9 Ferrer R, Artigas A, Levy MM et al. Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. JAMA: ; 2008. 299. 2294-2303
  • 10 Kortgen A, Niederprum P, Bauer M. Implementation of an evidence-based “standard operating procedure„ and outcome in septic shock. Crit Care Med 2006; 34: 943-949
  • 11 Dellinger RP, Levy MM, Rhodes A et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39: 165-228
  • 12 Chamberlain DJ, Willis EM, Bersten AB. The severe sepsis bundles as processes of care: a meta-analysis. Aust Crit Care 2011; 24: 229-243
  • 13 American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-874
  • 14 Howell MD, Talmor D, Schuetz P et al. Proof of principle: the predisposition, infection, response, organ failure sepsis staging system. Crit Care Med 2011; 39: 322-327
  • 15 Rosengarten B, Mayer K, Weigand MA. Clinical neurological diagnosis of sepsis-associated delirium. Nervenarzt. 2011 82. 1578-1583
  • 16 Barie PS, Hydo LJ, Shou J et al. Influence of antibiotic therapy on mortality of critical surgical illness caused or complicated by infection. Surg Infect 2005; 6: 41-54
  • 17 Puskarich MA, Trzeciak S, Shapiro NI et al. Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocol. Crit Care Med 2011; 39: 2066-2071
  • 18 Tripathi N, Watt K, Benjamin Jr DK. Treatment and prophylaxis of invasive candidiasis. Semin Perinatol 2012; 36: 416-423
  • 19 Bochud PY, Glauser MP, Calandra T. Antibiotics in sepsis. Intensive Care Med 2001; 27 (Suppl. 01) S33-S48
  • 20 Heyland DK, Johnson AP, Reynolds SC et al. Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Critical care medicine 2011; 39: 1792-1799
  • 21 Koeze J, Hendrix MG, van den Bergh FA et al. In critically ill patients the procalcitonin level can be misleading. Crit Care 2011; 15: 422
  • 22 Brunkhorst FM, Gastmeier P, Kern W et al. Prevention and follow-up care of sepsis. 1st revision of S2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V., DSG) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin, DIVI). Internist 2010; 51: 925-932
  • 23 Cardoso T, Ribeiro O, Aragao I et al. The impact of healthcare-associated infection on mortality: failure in clinical recognition is related with inadequate antibiotic therapy. PloS one 2013; 8: e58418
  • 24 Dellinger RP, Carlet JM, Masur H et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32: 858-873
  • 25 Schortgen F, Lacherade JC, Bruneel F et al. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001; 357: 911-916
  • 26 Gattinoni L, Caspani ML. Albumin and furosemide in acute lung injury: a little step forward?. Crit Care Med 2002; 30: 2376-2377
  • 27 Bendjelid K, Romand JA. Fluid responsiveness in mechanically ventilated patients: a review of indices used in intensive care. Intensive Care Med 2003; 29: 352-360
  • 28 Rivers E, Nguyen B, Havstad S et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368-1377
  • 29 Puskarich MA, Trzeciak S, Shapiro NI et al. Whole blood lactate kinetics in patients undergoing quantitative resuscitation for severe sepsis and septic shock. Chest 2013; 143: 1548-1553
  • 30 Martin C, Viviand X, Leone M et al. Effect of norepinephrine on the outcome of septic shock. Crit Care Med 2000; 28: 2758-2765
  • 31 Klompas M, Yokoe DS. Automated surveillance of health care-associated infections. Clin Infect Dis 2009; 48: 1268-1275
  • 32 Walkey AJ, Greiner MA, Heckbert SR et al. Atrial fibrillation among Medicare beneficiaries hospitalized with sepsis: incidence and risk factors. Am Heart J 2013; 165: 949-955 e943
  • 33 Liu X, Kruger PS, Weiss M et al. The pharmacokinetics and pharmacodynamics of cisatracurium in critically ill patients with severe sepsis. Br J Clin Pharmacol 2012; 73: 741-749
  • 34 Morgera S, Slowinski T, Melzer C et al. Renal replacement therapy with high-cutoff hemofilters: Impact of convection and diffusion on cytokine clearances and protein status. Am J Kidney Dis. 2004. 43. 444-453
  • 35 Joannidis M. Continuous renal replacement therapy in sepsis and multisystem organ failure. Seminars in dialysis 2009; 22: 160-164
  • 36 Vincent JL, Nadel S, Kutsogiannis DJ et al. Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies. Crit Care 2005; 9: R331-R343
  • 37 Annane D, Timsit JF, Megarbane B et al. Recombinant human activated protein C for adults with septic shock: a randomized controlled trial. Am J Respir Crit Care Med 2013; 187: 1091-1097
  • 38 Ranieri VM, Thompson BT, Barie PS et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366: 2055-2064
  • 39 Levi M, Levy M, Williams MD et al. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 2007; 176: 483-490
  • 40 Di Nisio M, Baudo F, Cosmi B et al. Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thrombosis research 2012; 129: e177-e184
  • 41 Opal SM, Laterre PF, Francois B et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA: ; 2013. 309. 1154-1162
  • 42 Kreymann KG, de Heer G, Nierhaus A et al. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007; 35: 2677-2685
  • 43 Lubbers T, Kox M, de Haan JJ et al. Continuous administration of enteral lipid- and protein-rich nutrition limits inflammation in a human endotoxemia model. Crit Care Med. 2013 41. 1258-1265
  • 44 Heidegger CP, Berger MM, Graf S et al. Optimisation of energy provision with supplemental parenteral nutrition in critically ill patients: a randomised controlled clinical trial. Lancet 2013; 381: 385-393
  • 45 Doig GS, Simpson F, Sweetman EA et al. Early parenteral nutrition in critically ill patients with short-term relative contraindications to early enteral nutrition: a randomized controlled trial. JAMA 2013; 309: 2130-2138
  • 46 Gadek JE, DeMichele SJ, Karlstad MD et al. Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Enteral Nutrition in ARDS Study Group. Crit Care Med 1999; 27: 1409-1420
  • 47 Goeters C, Wenn A, Mertes N et al. Parenteral L-alanyl-L-glutamine improves 6-month outcome in critically ill patients. Crit Care Med 2002; 30: 2032-2037
  • 48 Heyland D, Muscedere J, Wischmeyer PE et al. A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med 2013; 368: 1489-1497
  • 49 Kreymann KG, Berger MM, Deutz NE et al. ESPEN Guidelines on Enteral Nutrition: Intensive care. Clin Nutr 2006; 25: 210-223
  • 50 Reinhart K, Brunkhorst FM, Bone HG et al. Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI)). German medical science: GMS e-journal 2010; 8 Doc14